Get started
Author

Jasper Felten

Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses
2024 · Sikander Ailawadhi, Bertrand Arnulf, et al. · Blood · 78
Idecabtagene Vicleucel (ide-cel) Versus Standard (std) Regimens in Patients (pts) with Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Updated Analysis from KarMMa-3
2023 · Paula Rodríguez Otero, Sikander Ailawadhi, et al. · Blood · 16
P-008 Idecabtagene vicleucel (ide-cel) vs standard regimens in triple-class–exposed (TCE) relapsed and refractory multiple myeloma (RRMM): KarMMa-3 subgroup analysis in patients receiving bridging therapy
2023 · Hermann Einsele, Paula Rodriguez-Otero, et al. · Clinical Lymphoma Myeloma & Leukemia · 11
Idecabtagene Vicleucel (ide-cel) Versus Standard (std) Regimens in Patients (pts) with Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Analysis of Cytopenias and Infections in Pts from KarMMa-3
2023 · Rachid Baz, Paula Rodriguez Otero, et al. · Blood · 5
Idecabtagene Vicleucel (ide-cel) Versus Standard Regimens (SRs) in Triple-Class–Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): KarMMa-3 Subanalysis of Black Patients (pts)
2024 · Krina K. Patel, Paula Rodríguez-Otero, et al. · Transplantation and Cellular Therapy · 2
P-031 Idecabtagene vicleucel (ide-cel) vs standard regimens in patients with triple-class–exposed (TCE) relapsed and refractory multiple myeloma (RRMM): KarMMa-3 subgroup analysis by prior lines of therapy
2023 · Salomon Manier, Paula Rodriguez-Otero, et al. · Clinical Lymphoma Myeloma & Leukemia · 2
P-040 Idecabtagene vicleucel (ide-cel) versus standard regimens in patients with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): a KarMMa-3 high-risk subgroup analysis
2023 · Krina Patel, Paula Rodriguez-Otero, et al. · Clinical Lymphoma Myeloma & Leukemia · 2
MM-388 Idecabtagene Vicleucel (ide-cel) Versus Standard Regimens in Patients With Triple-Class–Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): A KarMMa-3 Analysis in High-Risk Subgroups
2023 · Krina Patel, Paula Rodríguez-Otero, et al. · Clinical Lymphoma Myeloma & Leukemia · 2
PDF
S195: Idecabtagene Vicleucel (ide-cel) Vs Standard Regimens in Patients With Triple-class–exposed (tce) Relapsed and Refractory Multiple Myeloma (rrmm): a Karmma-3 Analysis in High-risk Subgroups
2023 · Krina Patel, Paula Rodríguez-Otero, et al. · HemaSphere · 2
P866: Idecabtagene Vicleucel (ide-cel) Vs Standard Regimens in Patients With Triple-class–exposed (tce) Relapsed and Refractory Multiple Myeloma (rrmm): Karmma-3 Subgroup Analysis by Prior Lines of Therapy
2023 · Salomon Manier, Paula Rodríguez-Otero, et al. · HemaSphere · 2
POSTER: MM-388 Idecabtagene Vicleucel (ide-cel) Versus Standard Regimens in Patients With Triple-Class–Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): A KarMMa-3 Analysis in High-Risk Subgroups
2023 · Krina Patel, Paula Rodríguez-Otero, et al. · Clinical Lymphoma Myeloma & Leukemia · 1
Idecabtagene Vicleucel (Ide-Cel) Versus Standard Regimens (SRs) in Triple-Class–Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): KarMMa-3 Sub-Analysis of Black Patients
2024 · Krina K. Patel, Paula Rodríguez-Otero, et al. · Clinical Lymphoma Myeloma & Leukemia
MM-359 Idecabtagene Vicleucel (Ide-Cel) Versus Standard Regimens (SRs) in Triple-Class–Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): KarMMa-3 Sub-Analysis of Black Patients
2024 · Krina Patel, Paula Rodríguez-Otero, et al. · Clinical Lymphoma Myeloma & Leukemia
P-032 Ide-cel versus standard regimens in patients with triple-class–exposed (TCE) relapsed and refractory multiple myeloma (RRMM): a KarMMa-3 analysis in the modified intention to-treat (mITT) population
2023 · Salomon Manier, Sikander Ailawadhi, et al. · Clinical Lymphoma Myeloma & Leukemia
Works count: 15
Citation count: 123
H-index: 4
I10-index: 3
Year
Topic
Type